{"result": {"id": "34de9912-101a-4217-86d2-df99a292efe1", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>ARB<|>ORGANIZATION<|>ARB (Angiotensin Receptor Blockers) are a class of drugs used for treating hypertension, with minimal CYP450 enzyme metabolism interactions)\n##\n(\"entity\"<|>CYP450<|>ORGANIZATION<|>CYP450 is a family of enzymes responsible for metabolizing many drugs in the body)\n##\n(\"entity\"<|>RASS SYSTEM<|>ORGANIZATION<|>The RASS (Renin-Angiotensin-Aldosterone System) is a hormone system that regulates blood pressure and fluid balance)\n##\n(\"entity\"<|>Β-RECEPTOR BLOCKERS<|>ORGANIZATION<|>Beta-blockers are a class of drugs that block the effects of adrenaline, used for treating hypertension and other conditions)\n##\n(\"entity\"<|>CYP2D6<|>ORGANIZATION<|>CYP2D6 is an enzyme involved in the metabolism of many drugs, including some beta-blockers)\n##\n(\"entity\"<|>CYP3A4<|>ORGANIZATION<|>CYP3A4 is an enzyme involved in the metabolism of many drugs, including some beta-blockers and statins)\n##\n(\"entity\"<|>HMG-COA REDUCTASE INHIBITORS<|>ORGANIZATION<|>HMG-CoA reductase inhibitors (statins) are a class of drugs used to lower cholesterol levels)\n##\n(\"entity\"<|>NON-FELODIPINE<|>ORGANIZATION<|>Non-felodipine is a calcium channel blocker used for treating hypertension)\n##\n(\"entity\"<|>PROPRANOLOL<|>PERSON<|>Propranolol is a lipophilic beta-blocker metabolized by CYP2D6)\n##\n(\"entity\"<|>METOPROLOL<|>PERSON<|>Metoprolol is a lipophilic beta-blocker metabolized by CYP2D6)\n##\n(\"entity\"<|>BISOPROLOL<|>PERSON<|>Bisoprolol is a beta-blocker metabolized by CYP3A4)\n##\n(\"entity\"<|>ATENOLOL<|>PERSON<|>Atenolol is a hydrophilic beta-blocker that does not require CYP450 metabolism)\n##\n(\"entity\"<|>SIMVASTATIN<|>PERSON<|>Simvastatin is a lipophilic statin metabolized by CYP3A4)\n##\n(\"entity\"<|>LOVASTATIN<|>PERSON<|>Lovastatin is a lipophilic statin metabolized by CYP3A4)\n##\n(\"entity\"<|>ATORVASTATIN<|>PERSON<|>Atorvastatin is a lipophilic statin metabolized by CYP3A4)\n##\n(\"entity\"<|>ITRACONAZOLE<|>PERSON<|>Itraconazole is a strong CYP3A4 inhibitor)\n##\n(\"entity\"<|>KETOCONAZOLE<|>PERSON<|>Ketoconazole is a strong CYP3A4 inhibitor)\n##\n(\"entity\"<|>POSACONAZOLE<|>PERSON<|>Posaconazole is a strong CYP3A4 inhibitor)\n##\n(\"entity\"<|>VORICONAZOLE<|>PERSON<|>Voriconazole is a strong CYP3A4 inhibitor)\n##\n(\"entity\"<|>CLARITHROMYCIN<|>PERSON<|>Clarithromycin is a strong CYP3A4 inhibitor)\n##\n(\"entity\"<|>ERYTHROMYCIN<|>PERSON<|>Erythromycin is a strong CYP3A4 inhibitor)\n##\n(\"entity\"<|>TELITHROMYCIN<|>PERSON<|>Telithromycin is a strong CYP3A4 inhibitor)\n##\n(\"entity\"<|>AMIODARONE<|>PERSON<|>Amiodarone is a moderate CYP3A4 inhibitor)\n##\n(\"entity\"<|>AMLODIPINE<|>PERSON<|>Amlodipine is a moderate CYP3A4 inhibitor)\n##\n(\"entity\"<|>VERAPAMIL<|>PERSON<|>Verapamil is a moderate CYP3A4 inhibitor)\n##\n(\"entity\"<|>DILTIAZEM<|>PERSON<|>Diltiazem is a moderate CYP3A4 inhibitor)\n##\n(\"relationship\"<|>ARB<|>RASS SYSTEM<|>ARB drugs interact with the RASS system to regulate blood pressure<|>8)\n##\n(\"relationship\"<|>PROPRANOLOL<|>CYP2D6<|>Propranolol is metabolized by CYP2D6<|>8)\n##\n(\"relationship\"<|>METOPROLOL<|>CYP2D6<|>Metoprolol is metabolized by CYP2D6<|>8)\n##\n(\"relationship\"<|>BISOPROLOL<|>CYP3A4<|>Bisoprolol is metabolized by CYP3A4<|>8)\n##\n(\"relationship\"<|>SIMVASTATIN<|>CYP3A4<|>Simvastatin is metabolized by CYP3A4<|>8)\n##\n(\"relationship\"<|>LOVASTATIN<|>CYP3A4<|>Lovastatin is metabolized by CYP3A4<|>8)\n##\n(\"relationship\"<|>ATORVASTATIN<|>CYP3A4<|>Atorvastatin is metabolized by CYP3A4<|>8)\n##\n(\"relationship\"<|>ITRACONAZOLE<|>CYP3A4<|>Itraconazole inhibits CYP3A4<|>9)\n##\n(\"relationship\"<|>KETOCONAZOLE<|>CYP3A4<|>Ketoconazole inhibits CYP3A4<|>9)\n##\n(\"relationship\"<|>POSACONAZOLE<|>CYP3A4<|>Posaconazole inhibits CYP3A4<|>9)\n##\n(\"relationship\"<|>VORICONAZOLE<|>CYP3A4<|>Voriconazole inhibits CYP3A4<|>9)\n##\n(\"relationship\"<|>CLARITHROMYCIN<|>CYP3A4<|>Clarithromycin inhibits CYP3A4<|>9)\n##\n(\"relationship\"<|>ERYTHROMYCIN<|>CYP3A4<|>Erythromycin inhibits CYP3A4<|>9)\n##\n(\"relationship\"<|>TELITHROMYCIN<|>CYP3A4<|>Telithromycin inhibits CYP3A4<|>9)\n##\n(\"relationship\"<|>AMIODARONE<|>CYP3A4<|>Amiodarone moderately inhibits CYP3A4<|>6)\n##\n(\"relationship\"<|>AMLODIPINE<|>CYP3A4<|>Amlodipine moderately inhibits CYP3A4<|>6)\n##\n(\"relationship\"<|>VERAPAMIL<|>CYP3A4<|>Verapamil moderately inhibits CYP3A4<|>6)\n##\n(\"relationship\"<|>DILTIAZEM<|>CYP3A4<|>Diltiazem moderately inhibits CYP3A4<|>6)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166487, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1670, "prompt_tokens": 2517, "total_tokens": 4187, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 725}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 、 氯沙坦、替 米沙坦等，绝大多数在体内也不经过CYP450 酶代谢， 药动学相互作用较少见。ARB 与保钾利尿药合用可导 致血钾升高；糖尿病患者合用 ARB 和阿利吉仑，双重 阻断 RASS 系统，能加重低血压、高血钾和肾功能恶化 的风险，应该避免合用。\n\n\n4.2.3     β- 受体阻滞剂  脂溶性 β- 受体阻滞剂（ 如 普萘洛尔、 美托洛尔等）体内主要经 CYP2D6 代谢。  CYP2D6 抑制剂（ 如普罗帕酮、美托洛尔、氟西汀、帕  罗西汀等）可能减慢其代谢，导致严重心动过缓，特别 是目前强调“双心治疗”而合用抗抑郁症药物时。比索 洛尔在体内经 CYP3A4 代谢，与 CYP3A4 强抑制剂可能 存在药物相互作用。水溶性 β- 受体阻滞剂（如阿替洛 尔）不需要CYP450 酶代谢，一般不存在代谢性相互作用。\n　　与其他负性肌力或负性频率的药物（如维拉帕米） 合用能增强 β- 受体阻滞剂的房室传导阻滞的风险。\n　　降压药相关药物相互作用的潜在危害及处置见 表 2。\n4.3    血脂调节药\n　4.3.1    3- 羟基 -3- 甲基戊二酸单酰辅酶 A（HMG-CoA ） 还原酶抑制剂（他汀类）  辛伐他汀、洛伐他汀和阿托  伐他汀为脂溶性他汀类药物，在体内主要通过 CYP3A4   代谢，CYP3A4 强抑制剂（ 如伊曲康唑、酮康唑、泊沙  康唑、伏立康唑、克拉霉素、红霉素、泰利霉素）合用  显著减慢其代谢，增加横纹肌溶解风险。辛伐他汀合用  中等强度 CYP3A4 抑制剂（如胺碘酮或氨氯地平）时 日  剂量不能超过 20 mg ，合用维拉帕米、地尔硫卓时辛伐  他汀日剂量不能超过 10 mg。\n\n\n\nhttp://www.chinagp.net   E-mail:zgqkyx@chinagp.net.cn     ·3537 ·\n表 2    降压药相关药物相互作用的潜在危害及处置\nTable 2     Potential risk and management of drug interactions in the treatment of hypertension\n药物名称\t联合药物\t临床后果\t药动学改变\t相互作用机制\t临床建议\n非洛地平\t伊曲康唑\t低血压\t合用伊曲康唑使非洛地平 Cmax 升高近 8 倍， AUC0 → infinity 增加近 6 倍，t1/2 延长近 2 倍\t伊曲康唑抑制肠道和肝脏对非洛地平的 代谢，显著增加其血浆暴露量\t避免合用\n非洛地平\t红霉素\t低血压\t红霉素使非洛地平的 AUC 增加 7 倍，Cmax 升高 7 倍，t1/2 延长 7 倍\t　红霉素通过抑制 CYP3A4 �\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_6769e19a276c1c15e78944166e1d7f2aee448ef40d083c9f730c2c16f0fe2e48_v2"}